multiple-dose administration to normal volunteers. Clin Pharmacol Ther (St. Louis)
1993;54:595–605.
Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel
R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is
enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin
Pharmacol Ther 2000a;68:6–12.
Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel
R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is
enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein [see
comment]. Clin Pharmacol Ther 2000b;68:6–12.
Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P,
von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B,
Kroemer HK, Siegmund W. Induction of P-glycoprotein by rifampin increases
intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Clin Pharmacol Ther 2000c;68:345–355.
Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P,
von Richter O, Warzok R, Hachenberg T, Kauffmann H-M, Schrenk D, Terhaag B,
Kroemer HK, Siegmund W. Induction of P-glycoprotein by rifampin increases
intestinal secretion of talinolol in human beings: a new type of drug/drug interaction.
Clin Pharmacol Ther 2000d;68:345–355.
Wiley JS, Jones SP, Sawyer WH, Paterson ARP. Cytosine arabinoside influx and
nucleoside transport sites in acute leukemia. J Clin Invest 1982;69:479–489.
Wiley JS, Taupin J, Jamieson GP, Snook M, Sawyer WH, Finch LR. Cytosine
arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic
lymphoma. J Clin Invest 1985;75:632–642.
Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for
leukemic cells in mice receiving Imatinib mesylate for Bcr/Abl-induced leukemia.
Blood 2003;101:5010–5013.
Wright AMP, Paterson ARP, Sowa B, Akabutu JJ, Grundy PE, Gati WP. Cytotoxicity
of 2-chlorodeoxyadenosine and arabinosylcytosine in leukaemic lymphoblasts from
paediatric patients: significance of cellular nucleoside transporter content. Br J
Haematol 2002;116:528–537.
Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: transport/
absorption/elimination interplay and development of a biopharmaceutics drug
disposition classification system. Pharm Res 2005;22:11–23.
Xia CQ, Liu N, Miwa G, Gan L-S. Use ofin vitromodels to study interactions
between the breast cancer resistant protein and its ligands. Drug Metab Rev
2004;36:53.
Xia CQ, Liu N, Yang D, Miwa G, Gan L-S. Expression, localization, and functional
characteristics of breast cancer resistance protein in Caco-2 cells. Drug Metab Dispos
2005a;33:637–643.
Xia CQ, Yang JJ, Gan L-S. Breast cancer resistance protein in pharmacokinetics and
drug–drug interactions. Expert Opin Drug Metab Toxicol 2005b;1:595–611.
Xia CQ, Xiao G, Liu N, Pimprale S, Fox L, Patten CJ, Crespi CL, Miwa G, Gan L-S.
Comparison of species differences of P-Glycoproteins in beagle dog, rhesus monkey,
and human using ATPase activity assays. Mol Pharm 2006;3:78–86.
REFERENCES 201